QR kód

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with severe hepatic impairment has been established. We pr...

Celý popis

Uloženo v:
Hlavní autoři: M. Czejka, A. Sahmanovic, P. Buchner, T. Steininger, C. Dittrich
Médium: Artigo
Jazyk:Inglês
Vydáno: Karger Publishers 2013-12-01
Edice:Case Reports in Oncology
Témata:
Pharmacokinetics
Erlotinib
OSI420
Bilirubin
Pancreatic cancer
Drug monitoring
On-line přístup:http://www.karger.com/Article/FullText/357211
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky